Metropolitan Life Insurance Company (MetLife)’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,246	Closed	-$5.82K	–	2462
2023 Q2	$5.82K	Hold	2,246	–	–	﹤0.01%	2447
2023 Q1	$9.16K	Sell	2,246 -146	-6%	-$675	﹤0.01%	2191
2022 Q4	$12K	Hold	2,392	–	–	﹤0.01%	2224
2022 Q3	$31.3K	Hold	2,392	–	–	﹤0.01%	1777
2022 Q2	$30.7K	Buy	2,392 +663	+38%	+$9.18K	﹤0.01%	1805
2022 Q1	$26.4K	Sell	1,729 -7,528	-81%	-$117K	﹤0.01%	1960
2021 Q4	$164K	Hold	9,257	–	–	﹤0.01%	2156
2021 Q3	$195K	Hold	9,257	–	–	﹤0.01%	2089
2021 Q2	$183K	Buy	9,257 +1,110	+14%	+$26K	﹤0.01%	2213
2021 Q1	$237K	Sell	8,147 -194	-2%	-$5.43K	﹤0.01%	1900
2020 Q4	$253K	Hold	8,341	–	–	﹤0.01%	1781
2020 Q3	$133K	Hold	8,341	–	–	﹤0.01%	2053
2020 Q2	$165K	Hold	8,341	–	–	﹤0.01%	1933
2020 Q1	$103K	Hold	8,341	–	–	﹤0.01%	2011
2019 Q4	$154K	Buy	+8,341	New	+$122K	﹤0.01%	2080

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NGM Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 2,246 shares — an estimated $5.82K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NGM in Q4 2019 and held it in 15 quarters. The position peaked at $253K in Q4 2020. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 2,246 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $5.82K.
Metropolitan Life Insurance Company (MetLife) first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 15 quarters.
Metropolitan Life Insurance Company (MetLife)'s NGM Biopharmaceuticals, Inc. Common Stock position peaked at $253K in Q4 2020.
94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.